Kooperativer Bibliotheksverbund

UID:

Umfang: 1 online resource (492 pages)

Ausgabe: First edition.

ISBN: 0-443-13206-2

Inhalt: Alzheimer's Disease and Advanced Drug Delivery Strategies compiles under a single volume the most recent advances in drug delivery to the brain as related to AD treatment. The book's editors recruited scientists from around the world to produce high quality chapters covering not only nanotechnological approaches, but also microsphere, niosomes, and liposomes. Among the topics covered are synthetic molecules, nobiletin, nose to brain delivery, natural biomaterials, cationic nanoformulations, dendrimers, microbubbles, and more. This book represents a complete reference for academic and corporate pharma researchers investigating targeted drug delivery to the brain.

Anmerkung: Includes index. , Front Cover -- ALZHEIMER'S DISEASE AND ADVANCED DRUG DELIVERY STRATEGIES -- ALZHEIMER'S DISEASE AND ADVANCED DRUG DELIVERY STRATEGIES -- Copyright -- Contents -- Contributors -- About the editors -- Preface -- Acknowledgments -- 1 - Etiology, pathogenesis of Alzheimer's disease and amyloid beta hypothesis -- 1. Introduction -- 2. Etiology of Alzheimer's disease -- 3. Pathogenesis of Alzheimer's disease -- 3.1 Amyloid deposition neuropathogenesis -- 3.2 Neurofibrillary changes based neuropathogenesis -- 4. Diagnosis of AD -- 5. Amyloid beta protein hypothesis -- 6. Consequences of amyloid beta (Aβ) formation -- 7. Genetic factors responsible for the Alzheimer's disease -- References -- 2 - Neuroinflammation in Alzheimer's disease -- 1. Introduction -- 2. History of neuroinflammation in AD -- 3. The concept of neuroinflammation in AD -- 4. Neuroinflammation: Causes and consequences of Alzheimer's disease -- 5. BBB integrity and neuroinflammation -- 6. Role of cellular players -- 6.1 Microglial -- 6.2 Astroglia -- 6.3 Blood-derived mononuclear cells -- 7. Role of mediators and modulators in neuroinflammation -- 7.1 Cytokines -- 7.2 Interleukin-1 (IL-1) -- 7.3 Interleukin-6 (IL-6) -- 7.4 Tumor necrosis factor-alpha (TNF-α) -- 7.5 Transforming growth factor beta (TGF-β) -- 7.6 Chemokines -- 7.7 Caspases -- 7.8 Inflammatory changes of neurovascular unit (NVU) -- 7.9 Analysis of altering immune response -- 7.10 Nitric oxide and reactive oxygen species -- 7.11 Complement system -- 8. Role of intracellular signaling pathway -- 8.1 Role of MAPK -- 8.2 Role of NF-κB -- 8.3 Role of PPAR-γ -- 9. Genetic studies -- 10. Imaging of neuroinflammation in AD -- 10.1 The in-vivo laser scanning microscope -- 10.2 The imaging of inflammation in animals -- 10.3 The imaging of inflammation in humans -- 11. Possible intervention of neuroinflammation in AD. , 11.1 Targeting inflammasome -- 11.2 Targeting CD38 -- 11.3 Targeting CD33 -- 11.4 Targeting TNF-alpha (TNF-α) -- 12. Factors associated with neuroinflammation -- 12.1 Traumatic brain injury (TBI) -- 12.2 Systemic inflammation -- 12.3 Obesity -- 12.4 Locus Coeruleus degeneration -- 13. Development of therapeutic potential -- 13.1 Antiinflammatory agents -- 13.2 Nutraceuticals -- 13.3 Essential vitamins and minerals -- 13.4 Antioxidants -- 14. Conclusion -- References -- 3 - Recent updates in chemistry of Alzheimer's: Synthetic molecules -- 1. Introduction -- 2. MTDL approach associated with following scaffold or structures -- 2.1 Acridine/tacrine analogs -- 2.2 Imidazoles and benzimidazoles -- 2.3 Coumarin and chromones -- 2.4 Donepezil analogs (indanone scaffold) -- 2.5 Indoles -- 2.6 Pyrazoles/pyrazolones -- 2.7 Triazoles -- 3. Conclusion -- References -- 4 - Blood brain barrier and its significance in drug delivery to brain in Alzheimer disease -- 1. Introduction -- 2. Blood brain barrier -- 3. Current treatments for AD -- 4. Emerging therapies for AD -- 5. Nanotherapeutics for AD -- 5.1 Polymeric nanoparticles -- 5.2 Lipidic-based systems -- 5.3 Metallic nanoparticles -- 5.4 Quantum dots -- 5.5 Dendrimers -- 5.6 RNA based systems -- 6. Other approaches for crossing BBB -- 6.1 Focused ultrasound (FUS) induced BBB opening -- 6.2 Implants -- 7. Conclusion and future perspective -- References -- 5 - Nose to brain delivery for the treatment of Alzheimer's disease -- 1. Introduction -- 2. The nose-to-brain (N2B) pathway -- 3. AZD and current treament -- 4. Development of N2B delivery for AZD -- 5. Approaches to modulation of N2B delivery in AZD -- 5.1 Solution -- 5.2 Mucoadhesive agents -- 5.3 Permeation enhancers -- 5.4 Colloidal carrier systems -- 5.4.1 Microemulsion -- 5.4.2 Nanoparticles -- 5.4.3 Nanosuspension -- 5.4.4 SLN and NLC. , 5.4.5 Liposomes -- 6. Advantages of N2B delivery for AZD -- 7. Conclusion and future directions -- References -- 6 - Amyloid cascade hypothesis, tau synthesis, and role of oxidative stress in AD -- 1. Introduction to the amyloid (amyloid-beta peptide) -- 2. Biogenesis of amyloid-beta -- 3. Amyloid cascade hypothesis (ACH) -- 4. Pros and cons of the ACH -- 4.1 Pros -- 4.2 Cons -- 5. Therapeutic targeting for amyloid-beta in Alzheimer's pathogenesis -- 5.1 Inhibiting amyloid-beta production -- 5.1.1 Alpha-secretase activators -- 5.1.1.1 Etazolate -- 5.1.1.2 EGCG -- 5.1.1.3 Bryostatin 1 -- 5.1.2 Beta-secretase blockers -- 5.1.2.1 Thiazolidinedione analogs (rosiglitazone and pioglitazone) -- 5.1.2.2 CTS-21166 -- 5.1.2.3 MK-8931 -- 5.1.3 Gamma-secretase blockers -- 5.1.3.1 LY-450139 -- 5.1.3.2 GSI-953 -- 5.1.3.3 BMS-708163 -- 5.2 Blocking amyloid-beta aggregation -- 5.2.1 Tramiprosate -- 5.2.2 Curcumin -- 5.2.3 Resveratrol -- 5.2.4 Quercetins -- 5.2.5 Metal chelators -- 5.3 Increasing amyloid-beta clearance -- 5.3.1 Direct vaccination (amyloid-beta vaccination) -- 5.3.2 Passive immunization -- 5.3.2.1 Bapineuzumab -- 5.3.2.2 Solanezumab -- 5.3.2.3 Gantenerumab -- 5.3.2.4 Crenezumab -- 6. Tau protein -- 6.1 Pathophysiology of tau -- 6.1.1 Pathology of tau -- 6.1.1.1 Hyperphosphorylation and oligomerization of tau -- 6.1.1.2 Microtubule binding and redistribution -- 6.1.1.3 Formation of paired helical filaments (PHFs) -- 6.1.1.4 Modifications of tau -- 6.1.1.5 Glycation and truncation of tau -- 6.1.2 Physiological roles of tau -- 6.2 Tau-based therapies -- 6.2.1 Kinases inhibition -- 6.2.1.1 GSK3 inhibitors -- 6.2.1.2 CDK five inhibitors -- 6.2.1.3 MARK/PAR1 as a target for inhibition -- 6.2.2 Phosphatases activators -- 6.2.3 Microtubule stabilization -- 6.2.4 Glycosylation protagonist -- 6.2.5 Chaperones -- 6.2.6 Immunotherapy -- 6.2.7 Autophagic clearance. , 7. Role of oxidative stress in AD -- 8. Corelation of amyloid B protein, tau process, and oxidative stress in AD -- References -- 7 - New biologicals and biomaterials in the therapy of Alzheimer's disease -- 1. Introduction -- 1.1 Alzheimer's pathophysiology -- 2. Potential target for Alzheimer's disease therapy -- 2.1 Targets associated with amyloid-beta (Aβ) protein -- 2.2 Targets associated with tau-protein -- 2.3 Targets associated with low levels of acetylcholine (ACh) -- 2.4 Genetic factors associated with Alzheimer -- 2.5 Role of dopamine and serotonin -- 2.6 Other potential targets -- 2.7 All FDA-approved therapies and modern research in the Alzheimer's disease -- 3. Biologicals used in therapy of Alzheimer's disease -- 3.1 Amyloid-beta therapeutic antibodies for AD -- 3.2 Tau therapeutic antibodies for AD -- 3.3 TREM2 therapeutic antibodies for AD -- 3.4 Neurotrophins for AD -- 3.5 TNF-α inhibitors for Alzheimer -- 3.6 Cell-based therapy -- 4. Biomaterials used in therapy of Alzheimer's disease -- 4.1 Implant-based drug delivery -- 4.1.1 Drug delivery and tissue engineering using implanted scaffolds -- 4.1.2 Injectable hydrogels for tissue engineering and drug delivery -- 4.2 Nanotechnology -- 5. Nanoparticles in the therapy of Alzheimer's disease -- 5.1 Curcumin-loaded nanoparticles -- 5.2 NP-mediated chelation -- 5.3 Nanoparticles loaded with iron (Fe) chelators -- 5.4 Copper chelators-induced nanoparticles -- 6. Metal nanoparticles for Alzheimer's disease treatment -- 6.1 Nanoparticles filled with cerium -- 6.2 Gold (Au) nanoparticles -- 6.3 Nanoparticles of selenium -- 7. Other NPs -- 7.1 Poly(butyl) cyanoacrylate (PBCA) NPs -- 7.2 Polymer-based NPs -- 7.3 Nano-particulates based on polysaccharides -- 7.4 Protein based nanoparticles -- 7.4.1 Functionalized synthetic polymers nanoparticles -- 7.5 NPs loaded with hormones. , 7.5.1 Melatonin loaded nanoparticles -- 7.6 Self-assembling nanostructures -- 7.7 Self-assembling nanogel -- 7.8 Poly(propylene imine) dendrimers -- 7.9 Nanoparticles decorated with antibody or its fragment -- 7.10 Exosomes like nano-vesicular carriers -- 8. Systems based on biomaterials for mass production of therapeutic cells -- 8.1 Therapeutic cell isolation and purification -- 8.2 Genomic modification of therapeutic cells -- 8.3 Mass production of therapeutic cells -- 8.4 Harvesting cells after mass production -- 8.5 Cryopreservation, banking, and shipping -- 9. Challenges of biomaterial-based drug delivery approach in Alzheimer's disease -- 10. Conclusion -- References -- 8 - Roles of nano medicine in diagnosis of Alzheimer's disease -- 1. Introduction -- 1.1 Alzheimer's disease diagnostic and therapeutic pipelines: Current state -- 1.2 Clinical criteria for diagnosis -- 1.3 Pathogenesis of AD concerning diagnosis -- 2. Diagnostic tools for AD -- 2.1 History of diagnosis of AD -- 2.2 How is Alzheimer's disease diagnosed? [31] -- 2.2.1 Brain-imaging technologies used in diagnosis of AD [31,32] -- 2.2.2 Biomarkers -- 2.2.2.1 Diagnostic markers -- 2.2.2.2 Blood and fluid biomarkers -- 2.2.2.3 Ocular markers -- 2.2.2.4 Others -- 2.2.3 Optical imaging (OI) -- 2.2.4 Localized nanosensor based on surface plasmon resonance -- 2.2.5 Scanning tunneling microscopy [STM] and two photon Rayleigh spectroscopy -- 2.3 Nanotechnology for diagnosis of AD -- 2.3.1 Nano-diagnostics for AD -- 2.3.2 Nanotechnologies to detect AD biomarkers in biological fluids -- 2.4 Nano particles or nano medicine as a tool for diagnosis of AD -- 2.5 Need of nanomedicine as diagnostic approach -- 2.6 Preclinical and clinical tools for diagnosis of AD with marketed formulations available for diagnosis -- 3. Future perspective of nano medicine and their effectiveness. , 4. Conclusion and limitations.

Weitere Ausg.: Print version: Prajapati, Bhupendra Alzheimer's Disease and Advanced Drug Delivery Strategies San Diego : Elsevier Science & Technology,c2023 ISBN 9780443132056

Sprache: Englisch